Learner Notification

Behind the Scenes Strandness Symposium February 11 – 15, 2024 Honolulu, HI

<u>Acknowledgement of Financial Commercial Support</u> Boston Scientific, Cook Medical, Gore, Medtronic, Silk Road Medical

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Accreditation Statement



INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Behind the Scenes. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME) Credit Designation

Amedco LLC designates this live activity for a maximum of 32.75 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Surgery (ABS) Credit Designation



Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the Self-Assessment requirements of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit. Up to 15.00 self-assessment hours available. You must request your certificate within 30 days of the activity to meet the deadline for submission to PARS.

Objectives - After Attending This Program You Should Be Able To

- 1. Discuss the interpretation criteria for carotid duplex scanning and the impact on patient.
- 2. Explain how to develop a quality assurance program for the vascular laboratory.
- 3. Discuss the role of medical therapy vs. surgical intervention for asymptomatic carotid disease.
- 4. Describe recent advances in vascular testing and endovascular interventions for trauma. Incorporate duplex scanning into a follow-up imaging program for patients having EVAR.
- 5. Discuss the guidelines for managing visceral artery aneurysms.
- 6. Use the latest evidence-based guidelines for management of venous thromboembolism.
- 7. Recognize the importance of technical protocols for venous reflux testing.
- 8. Outline the current options for treatment of varicose veins.
- 9. Discuss the classification, diagnosis and management of pelvic disorders.
- 10. Use duplex scanning for pre-dialysis access mapping and assessment of dialysis access maturation.
- 11. Define the role of the vascular laboratory in the management of critical limb ischemia.
- 12. Discuss the "optimal medical management" for peripheral artery disease.
- 13. Describe the indications for treating restenosis after peripheral artery interventions.
- 14. Explain how to recruit and retain vascular sonographers and address issues around diversity, equity and inclusion in the vascular laboratory.
- 15. Describe the features of normal and abnormal Doppler waveforms using the latest terminology.
- 16. Discuss the management of complex aortic aneurysms with open surgical repair and endovascular devices.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

| First Name | Last Name | Commercial Interest: Relationship |
|-------------------|-------------|---|
| Dennis | Bandyk | NA |
| George | Berdejo | NA |
| William | Bohannon | NA |
| Michael | Caps | NA |
| John | Carson | Boston Scientific:Consultant |
| Mabel | Chan | NA |
| David | Dawson | NA |
| Steven | Dean | Tactile Medical:Scientific/Medical Advisory Board Member |
| Rachel | Drgastin | NA |
| Mariah | Elliott | NA |
| Aravindh | Ganapathy | NA |
| Kathleen | Gibson | Gore:Consultant,Medtronic:Scientific/Medical Advisory Board Member,Boston Scientific:Scientific/Medical Advisory Board Member,Philips:Speakers Bureau,Janssen:Speakers Bureau |
| Ryan | Hagino | NA |
| Karem | Harth | Boston Scientific:Consultant,Medtronic:Consultant,Inari:Consultant,Cook:Speakers Bureau,GE:Speakers Bureau,Phillips:Consultant,MedVasc:Scientific/Medical Advisory Board Member,Inquis:Consultant |
| Jake | Hemingway | NA |
| Joseph | Hughes | NA |
| Michael | Jaff | Efemoral:Stock Shareholder,Boston Scientific:Employee,Gilde Healthcare:Consultant,Vascular Therapies:Stock Shareholder,Access Vascular:Corporate Board Member,HeartBeam:Corporate Board Member |
| Claire | Janssen | NA |
| Soo Hyun (Esther) | Kim | NA |
| Yulia | Kostenko | NA |
| Matthew | Leverich | NA |
| Taleen | MacArthur | NA |
| Karen | Man | NA |
| Karen | Man | NA |
| Elna | Masuda | NA |
| Mark | Meissner | NA |
| Frank | Miele | Samsung:Other |
| Joseph | Mills | NA |
| Aarathi | Minisandram | NA |
| Greg | Moneta | NA |
| John | Pellerito | NA |
| Alejandro | Pizano | NA |
| Kylie | Pluim | NA |
| Chien Yi | Png | NA |
| Tracey | Reid | NA |
| Catherine | Rienzo | NA |
| Christopher | Riley | NA |
| Alley | Ronaldi | NA |
| Thom | Rooke | Osborn Medical:Consultant,Huntleigh LTD:Patent Holder |
| Denny | Scaria | NA |

All individuals in a position to control the content of CE are listed below.

| Peter | Schneider | Medtronic:Scientific/Medical Advisory Board Member,Boston Scientific:Scientific/Medical Advisory Board Member,Surmodics:Consultant,Silk Road Medical:Consultant,Philips:Consultant,Cagent:Consultant,Limflow:Consultant,Endolo gix:Consultant,Acotec:Consultant |
|-----------|------------|--|
| Martyna | Schonborn | NA |
| Jo | Shultz | NA |
| Meryl | Simon | NA |
| Niten | Singh | Cook:Consultant |
| Sara | Skjonsberg | EnVVeno Medical Corporation : Employee |
| watson | Smith | NA |
| Antonio | Solano | NA |
| Jill | Sommerset | Abbott:Consultant,Philips |
| | | :Consultant,Moonrise:Consultant,Aveera:Consultant,BD:Consultant |
| Kourtney | Spencer | NA |
| Nicolas | Stafforini | NA |
| Maria | Stanczk | Lantheus:Consultant,Siemens Medical:Consultant |
| Ben | Starnes | Terumo Aortic:Consultant |
| Jordan | Strom | Edwards Lifesciences:Scientific/Medical Advisory Board Member,Edwards Lifesciences:Research Grant Overall Principal Investigator,Ultromics:Research Grant Overall Principal Investigator,HeartSciences:Research Grant Site Principal Investigator,Bracco Diagnostics:Consultant,Anumana:Research Grant Overall Principal Investigator,General Electric:Consultant,EcholQ:Scientific/Medical Advisory Board Member,Ultromics:Scientific/Medical Advisory Board Member,Phillips Healthcare:Consultant,EcholQ:Research Grant Overall Principal Investigator,Lantheus Medical Imaging:Research Grant Overall Principal Investigator |
| Shima | Tafreshi | NA |
| David | Walker | NA |
| Molly | Zaccardi | NA |
| R. Eugene | Zierler | NA |

| Sunday, February 11, 2024 | | |
|---------------------------|------|--|
| 7:30 am - 10:00 am | 2.50 | Course Overview, Hemodynamic Principles, Physics and Instrumentation (Part 1), |
| | 2.50 | Waveform Description and Analysis, Physics and Instrumentation (Part 2) |
| 10:20 am 12:15 nm | 1.75 | Physics and Instrumentation (Part 3), Case Studies, Practical Approaches for |
| 10:30 am - 12:15 pm | | Interpretation and Reporting, Preparing for Certification |
| 12:15 pm - 1:30 pm | 0.75 | Lunch -Round Table Discussions |
| 1:30 pm - 2:00 pm | 0.50 | Imaging Demonstrations |
| 2:30 pm - 5:30 pm | 3.00 | Vascular Forum Scientific Session |

| 2:30 pm - 5:30 pm | 3.00 | Vascular Forum Scientific Session | |
|---------------------|------|---|--|
| | | | |
| | | Monday, February 12, 2024 | |
| 8:00 am - 9:40 am | 1.75 | Session 1: Cerebrovascular Disease | |
| 10:10 am - 12:15 pm | 2.00 | Session 2: New Technologies, Applications, and Opportunities | |
| 1:20 pm - 4:30 pm | 3.25 | Workshop A RPVI Case-Based Interpretation Review | |
| 2:00 pm - 3:00 pm | 1.00 | Workshop B Scan Lab: Carotid Duplex and Transcranial Doppler | |
| 3:00 pm - 4:00 pm | 1.00 | Workshop B REPEAT Scan Lab: Carotid Duplex and Transcranial Doppler | |
| 6:30 pm - 9:00 pm | 2.00 | Vascular Forum Dinner Program | |

| Tuesday, February 13, 2024 | | |
|----------------------------|------|--|
| 8:00 am - 9:40 am | 1.75 | Session 3: Upper Extremity Arterial Disease and Hemodialysis Access |
| 10:10 am - 12:15 pm | 2.00 | Session 4: Chronic Limb-Threatening Ischemia and Medical Management of PAD |
| 2:00 pm - 3:00 pm | 1.00 | Workshop C Scan Lab: Peripheral Arterial, Dialysis Access, Pedal Acceleration Time |
| | | Workshop D Laboratory Practice Issues: Accreditation, Credentialing, Quality |
| | | Improvement |
| 3:00 pm - 4:00 pm | 1.00 | Workshop C Scan Lab: Peripheral Arterial, Dialysis Access, Pedal Acceleration Time |

| | Workshop D Laboratory Practice Issues: Accreditation, Credentialing, Quality |
|--|--|
| | Improvement |

| Wednesday, February 14, 2023 | | |
|------------------------------|------|---|
| 8:00 am - 9:40 am | 1.75 | Session 5: Venous Disease I |
| 10:10 am - 12:15 pm | 2.00 | Session 6: Aorta and Visceral Vascular |
| 2:00 pm - 3:00 pm | 1.00 | Workshop E Scan Lab: Aorta, Renal/Mesenteric, and EVAR Follow-up |
| | | Workshop F Scan Lab: Venous Obstruction, Reflux, and Pelvic Disorders |
| 3:00 pm - 4:00 pm | 1.00 | Workshop E Scan Lab: Aorta, Renal/Mesenteric, and EVAR Follow-up |
| | | Workshop F Scan Lab: Venous Obstruction, Reflux, and Pelvic Disorders |

| Thursday, February 15, 2023 | | |
|-----------------------------|------|--|
| 8:00 am - 9:40 am | 1.75 | Session 7: Venous Disease II |
| 10:10 am - 12:15 pm | 2.00 | Session 8: Challenges and Controversies in Vascular Practice |